Siegfried Holding AG (Siegfried) manufactures pharmaceutical ingredients and finished products. It focuses on the development and production of finished dosage forms, active pharmaceutical ingredients (APIs), intermediates, and other products. Siegfried has manufacturing sites in Switzerland, the US, Malta, China, Germany, France, and Spain. The company also provides services such as chemical development, analytical development, pilot manufacturing and scale-up, contract development and manufacturing, and licensing. The company also offers end-to-end viral vector manufacturing solutions to progress gene therapy projects from DNA design to commercial scale. Siegfried operates through two product categories: Drug Substances and Drug Products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Siegfried has undertaken several R&D initiatives focused on green process development, circular economy innovations, and sustainability. The company has developed a process efficiency dashboard and a green chemistry dashboard to assess and improve the environmental performance of chemical processes. Additionally, R&D initiatives include enhancing energy efficiency, implementing recycling programs, and developing more efficient and sustainable synthesis routes. The company also focuses on reducing emissions through sophisticated distillation processes and purchasing renewable energy to lower Scope 2 GHG emissions. The R&D unit which is responsible for revisiting current manufacturing processes and developing more efficient and sustainable synthesis routes. The team also supports the operational excellence network in identifying and implementing efficiency and savings opportunities in manufacturing operations. In FY2025, the company spent CHF46.1 million on R&D, which ,as a percentage of revenue, stood at 3.4% and grew 12.3% YoY.